USH1992HExpiredUtilityPatentIndex 62
Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their pharmaceutical uses

Assignee: AGOURON PHARMAPriority: May 9, 1997Filed: Aug 11, 1999Granted: Sep 4, 2001
Est. expiryMay 9, 2017(expired)· nominal 20-yr term from priority
Inventors:BENDER STEVEN L CASTELHANO ARLINDO L
C07D 403/12C07D 213/42C07D 207/26C07D 231/12C07C 311/29C07D 401/12C07D 413/12C07D 405/12C07D 261/08C07D 213/68C07D 213/32C07D 233/64C07D 309/06C07D 223/06C07F 9/4006C07D 211/34C07D 211/20C07D 211/60
PatentIndex Score
Cited by
References
Claims
Abstract

The present invention relates to compounds of formula I: wherein Ar is an aryl group or a heteroaryl group; X is —NH—OH or —OH; R 1 is H, —CH(R 3 )(R 4 ), —C(O)R 3 , a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group, wherein R 3 is H or any suitable substituent and R 4 is H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group; R 2 is CH 2 -R 5 , wherein R 5 is H or any suitable substituent, or wherein R 5 and R 4 are optionally substituted carbon atoms singly- or double-bonded to one another; and pharmaceutically acceptable prodrugs, salts, and solvates thereof. The invention further relates to methods of using these compounds, particularly as metalloproteinase inhibitors.
Claims

exact text as granted — not AI-modified
What is claimed is:  
     
       1. A compound of formula l:                    
       wherein: 
       Ar is an aryl group or a heteroaryl group;  
       X is —NH—OH or —OH:  
       R 1  is H, —CH(R 3 )(R 4 ), —C(O)R 3 , a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group,  
       wherein R 3  is H or any suitable substituent and R 4  is H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group;  
       R 2  is CH 2 -R 5 , wherein R 5  is H or any suitable substituent, or wherein R. and R 4  are optionally substituted carbon atoms singly- or double-bonded to one another;  
       or a pharmaceutically acceptable prodrug, salt or solvate thereof. 
     
     
       2. A compound according to claim  1 , wherein R 3  is hydrogen, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, —OR 10 , —SR 10 , C≡C-R 10 , —C(O)OR 10 , C(O)NHR 10 , wherein R 10  is hydrogen, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group; or a pharmaceutically acceptable prodrug, salt, or solvate thereof. 
     
     
       3. A compound according to claim  1 , wherein said compound has the formula II:                    
       wherein R 1 , R 2 , and X are as defined in claim  1  and Z is a halogen group, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an O-alkyl group, an S-alkyl group, an aryl group, or a heteroaryl group; or a pharmaceutically acceptable prodrug, salt, or solvate thereof. 
     
     
       4. A compound according to claim  1 , wherein Ar is a heteroaryl group containing six ring atoms; or a pharmaceutically acceptable prodrug, salt, or solvate thereof. 
     
     
       5. A compound according to claim  4 , wherein Ar is pyridyl, pyrimidinyl, pyridazinyl, or pyrazinyl; or a pharmaceutically acceptable prodrug, salt, or solvate thereof. 
     
     
       6. A compound according to claim  1 , wherein R 5  is H and R 4  is an alkyl group; or a pharmaceutically acceptable prodrug, salt, or solvate thereof. 
     
     
       7. A compound according to claim  1 , wherein R 5  is a heteroaryl group; or a pharmaceutically acceptable prodrug, salt, or solvate thereof. 
     
     
       8. A compound according to claim  1 , wherein R 5  is —CHR 6 R 7 , wherein R 6  is H or any suitable substituent and R 7  is                    
       wherein R 8  is any suitable substituent; or a pharmaceutically acceptable prodrug, salt, or solvate thereof. 
     
     
       9. A compound according to claim  1 , wherein R 4  is an alkyl group and R 3  is an alkyl group, an O-alkyl group, or an S-alkyl group; or a pharmaceutically acceptable prodrug, salt, or solvate thereof. 
     
     
       10. A compound according to claim  9 , wherein R 3  is a —CH 2 CH 2 -heteroaryl group, an —OCH 2 —; heteroaryl group, or an —S—CH 2 -heteroaryl group; or a pharmaceutically acceptable prodrug, salt, or solvate thereof. 
     
     
       11. A compound according to claim  1 , wherein R 4  and R 5  together form the group —CH 2 CH 2 —; or a pharmaceutically acceptable prodrug, salt, or solvate thereof. 
     
     
       12. A compound according to claim  1 , wherein the compound is: 
       2(R)-1-[4-(4-Bromophenoxy)benzenesulfonyl]-N-hydroxy-piperidine-2-carboxamide,  
       2(R)-1-[4-(4-Chlorophenoxy)benzenesulfonyl]-N-hydroxy-piperidine-2-carboxamide,  
       2(R)-1-[4-(4-Fluorophenoxy)benzenesulfonyl]-N-hydroxy-piperidine-2-carboxamide,  
       2(R)-1-[4-(4-Methylphenoxy)benzenesulfonyl]-N-hydroxy-piperidine-2-carboxamide,  
       2(R)-1-[4-(4-Methoxyphenoxy)benzenesulfonyl]-N-hydroxy-piperidine-2-carboxamide,  
       2(R)-1-[4-Phenoxybenzenesulfonyl]-N-hydroxy-piperidine-2-carboxamide,  
       2(R)-1-[4-(Biphenyl-4-yl)oxybenzenesulfonyl]-N-hydroxy-piperidine-2-carboxamide,  
       2(R)-1-[4-(4-(Imidazol-1-yl)phenoxy)benzenesulfonyl]-N-hydroxy-piperidine-2-carboxamide,  
       2(R)-1-[4-(4-(Imidazol-2-yl)phenoxy)benzenesulfonyl]-N-hydroxy-piperidine-2-carboxamide,  
       2(R)-1-[4-(4-(Imidazol-4-yl)phenoxy)benzenesulfonyl]-N-hydroxy-piperidine-2-carboxamide,  
       2(R)-1-[4-(4-(Pyrazol-4-yl)phenoxy)benzenesulfonyl]-N-hydroxy-piperidine-2-carboxamide,  
       2(R)-1-[4-(4-(Pyrazol-3-yl)phenoxy)benzenesulfonyl]-N-hydroxy-piperidine-2-carboxamide,  
       2(R)-1-[4-(4-(2-(Dimethylamino)ethyl)phenoxy)benzenesulfonyl]-N-hydroxy-piperidine-2-carboxamide,  
       2(R)-1-[4-(Pyrid-4-yl)oxybenzenesulfonyl]-N-hydroxypiperidine-2-carboxamide,  
       2(R), 3(S)-1-[4-(4-Chlorophenoxy)benzenesulfonyl]-N-hydroxy-3-methyl-piperidine-2-carboxamide,  
       2(R), 3(S)-1-[4-(4-Fluorophenoxy)benzenesulfonyl]-N-hydroxy-3-methyl-piperidine-2-carboxamide,  
       2(R), 3(S)-1-[4-(4-Methoxyphenoxy)benzenesulfonyl]-N-hydroxy-3-methyl-piperidine-2-carboxamide,  
       2(R), 3(S)-1-[4-(4-(Imidazol-1-yl)phenoxy)benzenesulfonyl]-N-hydroxy-3-methyl-piperidine-2-carboxamide,  
       2(R), 3(S)-1-[4-(4-(Imidazol-2-yl)phenoxy)benzenesulfonyl]-N-hydroxy-3-methyl-piperidine-2-carboxamide,  
       2(R), 3(S)-1-[4-(4-(Imidazol-4-yl)phenoxy)benzenesulfonyl]-N-hydroxy-3-methyl-piperidine-2-carboxamide,  
       2(R), 3(S)-1-[4-(4-(Pyrazol-4-yl)phenoxy)benzenesulfonyl]-N-hydroxy-3-methyl-piperidine-2-carboxamide,  
       2(R), 3(S)-1-[4-(4-(Pyrazol-3-yl)phenoxy)benzenesulfonyl]-N-hydroxy-3-methyl-piperidine-2-carboxamide,  
       2(R), 3(S)-1-[4-(Pyrid-4-yl)oxybenzenesulfonyl]-N-hydroxy-3-methyl-piperidine-2-carboxamide,  
       2(R)-2-[4-(4-Bromophenoxy)benzenesulfonyl][(pyridin-3-yl)methyl]amino-N-hydroxy-3-methylbutanamide,  
       2(R)-2-[4-(4-Chlorophenoxy)benzenesulfonyl][(pyridin-3-yl)methyl]amino-N-hydroxy-3-methylbutanamide,  
       2(R)-2-[4-(4-Chlorophenoxy)benzenesulfonyl][(pyridin4-yl)methyl]amino-N-hydroxy-3-methylbutanamide,  
       2(R)-2-[4-(4-Chlorophenoxy)benzenesulfonyl][(imidazol-2-yl)methyl]amino-N-hydroxy-3-methylbutanamide,  
       2(R)-2-[4-(4-Chlorophenoxy)benzenesulfonyl][2-(imidazol-2-yl)ethyl]amino-N-hydroxy-3-methylbutanamide,  
       2(R)-2-[4-(4-Chlorophenoxy)benzenesulfonyl][2-(imidazol-4-yl)ethyl]amino-N-hydroxy-3-methylbutanamide,  
       2(R)-2-[4-(4-Chlorophenoxy)benzenesulfonyl][2-(pyrazol-3-yl)ethyl]amino-N-hydroxy-3-methylbutanamide,  
       2(R)-2-[4-(4-Chlorophenoxy)benzenesulfonyl][2-(methylcarbamoyl)ethyl]amino-N-hydroxy-3-methylbutanamide,  
       2(R)-2-[4-(4-Chlorophenoxy)benzenesulfonyl][2-(methylamino)ethyl]amino-N-hydroxy-3-methylbutanamide,  
       2(R)-2-[4-(4-Chlorophenoxy)benzenesulfonyl][(pyridin-3-yl)methyl]amino-N-hydroxy-2-cyclohexylacetamide,  
       2(R)-2-[4-(4-Chlorophenoxy)benzenesulfonyl][2-(imidazol-2-yl)ethyl]amino-N-hydroxy-2-cyclohexylacetamide,  
       2(R)-2-[4-(4-Chlorophenoxy)benzenesulfonyl][2-(methylcarbamoyl)ethyl]amino-N-hydroxy-2-cyclohexylacetamide,  
       2(R)-2-[4-(4-Chlorophenoxy)benzenesulfonyl][(pyridin-3-yl)methyl]amino-N-hydroxy-2-(tetrahydro-2H-pyran-4-yl)acetamide,  
       2(R)-2-[4-(4-Chlorophenoxy)benzenesulfonyl][2-(methylcarbamoyl)ethyl]amino-N-hydroxy-2-(tetrahydro-2H-pyran-4-yl)acetamide,  
       2(R)-2-[4-(4-Chlorophenoxy)benzenesulfonyl][(pyridin-3-yl)methyl]amino-N-hydroxy-2-(1-methylpiperidin-4-yl)acetamide,  
       2(R)-2-[4-(4-Chlorophenoxy)benzenesulfonyl][(pyridin-3-yl)methyl]amino-N-hydroxy-2-(1-acetylpiperidin-4-yl)acetamide,  
       2(R)-2-[4-(4-Chlorophenoxy)benzenesuifonyl][(2-(methylcarbamoyl)ethyl]amino-N-hydroxy-2-(1-methylpiperidin-4-yl)acetamide,  
       2(R), 3(R)-2-[4-(4-Chlorophenoxy)benzenesulfonyl](methyl)amino-N,3-dihydroxybutanamide,  
       2(R), 3(R)-2-[4-(4-Chlorophenoxy)benzenesulfonyl](methyl)amino-N-hydroxy-3-methoxybutanamide,  
       2(R), 3(R)-2-[4-(4-Chlorophenoxy)benzenesulfonyl](methyl)amino-N-hydroxy-3-(2-methoxyethoxy)butanamide,  
       2(R), 3(R), 3(2′(S))-2-[4-(4-Chlorophenoxy)benzenesulfonyl](methyl)amino-N-hydroxy-3-[(5-oxopyrrolidin-2-yl)methoxy]butanamide,  
       2(R), 3(R)-2-[4-(4-Chlorophenoxy)benzenesulfonyl](methyl)amino-N-hydroxy-3-[(1-methylimidazol-2-yl)methoxy]butanamide,  
       2(R)-2-[4-(4-Chlorophenoxy)benzenesulfonyl](methyl)amino-N-hydroxy-2-(1-methylpiperidin-4-yl)acetamide,  
       2(R)-2-[4-(4-Chlorophenoxy)benzenesulfonyl](methyl)amino-N-hydroxy-2-cyclohexylacetamide,  
       2(R)-2-[4-(4-Chlorophenoxy)benzenesulfonyl](methyl)amino-N-hydroxy-2-(tetrahydro-2H-pyran-4-yl)acetamide,  
       2(S) 3(R)-2-[4-(4-Chlorophenoxy)benzenesulfonyl)(methyl)amino-N-hydroxy-3-[(5-methylisoxazol-3-yl)methylsulfanyl]butanamide,  
       2(S), 3(R)-2-[4-(4-Chlorophenoxy)benzenesulfonyl](methyl)amino-N-hydroxy-3-[(pyrid-2-yl)methylsulfanyl]butanamide,  
       2(S), 3(R)-2-[4-(4-Chlorophenoxy)benzenesulfonyl](methyl)amino-N-hydroxy-3-[(1-methylimidazol-2-yl)methylsulfanyl]butanamide,  
       2(S), 3(R)-2-[4-(4-Chlorophenoxy)benzenesulfonyl](methyl)amino-N-hydroxy-3-[(1-methylpiperidin-4-yl)methylsulfanyl]butanamide,  
       2(S), 3(R)-2-[4-(4-Chlorophenoxy)benzenesulfonyl](methyl)amino-N-hydroxy-3-[2-(dimethylamino)ethylsulfanyl]butanamide,  
       2(S)-2-[4-(4-Chlorophenoxy)benzenesulfonyl](methyl)amino-N-hydroxy-3-[(5-methylisoxazol-3-yl)methylsulfanyl]propanamide,  
       2(S)-2-(4-(4-Chlorophenoxy)benzenesulfonyl](methyl)amino-N-hydroxy-3-[(pyrid-2-yl)methylsulfanyl]propanamide,  
       2(S)-2-[4-(4-Chlorophenoxy)benzenesulfonyl](methyl)amino-N-hydroxy-3-[(1-methylimidazol-2-yl)methylsulfanyl]propanamide,  
       2(R), 3(R)-2-[4-(4-Fluorophenoxy)benzenesulfonyl](methyl)amino-N,3-dihydroxybutanamide,  
       2(R), 3(R)-2-[4-(4-Fluorophenoxy)benzenesulfonyl](methyl)amino-N-hydroxy-3-methoxybutanamide,  
       2(R), 3(R)-2-[4-(4-Fluorophanoxy)bnenene sulfonyl](methyl)amino-N-hydroxy-3-(2-methoxyethoxy)butanamide,  
       2(R), 3(R), 3(2′(S))-2-[4-(4-Fluorophenoxy)benzenesulfonyl](methyl)amino-N-hydroxy-3-[(5-oxopyrrolidin-2-yl)methoxy]butanamide,  
       2(R), 3(R)-2-[4-(4-Fluorophenoxy)benzenesulfonyl](methyl)amino-N-hydroxy-3-[(1-methylimidazol-2-yl)methoxy]butanamide,  
       2(R)-2-[4-(4-Fluorophenoxy)benzenesulfonyl](methyl)amino-N-hydroxy-2-(1-methylpiperidin-4-yl)acetamide,  
       2(R)-2-[4-(4-Fluorophenoxy)benzenesulfonyl](methyl)amino-N-hydroxy-3-methylbutanamide,  
       2(R)-2-[4-(4-Fluorophenoxy)benzenesulfonyl](methyl)amino-N-hydroxy-2-cyclohexylacetamide,  
       2(R)-2-[4-(4-Fluorophenoxy)benzenesulfonyl](methyl)amino-N-hydroxy-2-(tetrahydro-2H-pyran-4-yl)acetamide,  
       2(S), 3(R)-2-[4-(4-Fluorophenoxy)benzenesulfonyl](methyl)amino-N-hydroxy-3-[(5-methylisoxazol-3-yl)methylsulfanyl]butanamide,  
       2(S), 3(R)-2-[4-(4-Fluorophenoxy)benzenesulfonyl](methyl)amino-N-hydroxy-3-[(pyrid-2-yl)methylsulfanyl]butanamide,  
       2(S), 3(R)-2-[4-(4-Fluorophenoxy)benzenesulfonyl](methyl)amino-N-hydroxy-3-[(1-methylimidazol-2-yl)methylsulfanyl]butanamide,  
       2(S), 3(R)-2-[4-(4-Fluorophenoxy)benzenesulfonyl](methyl)amino-N-hydroxy-3-[(1-methylpiperidin-4-yl)methylsulfanyl]butanamide,  
       2(S), 3(R)-2-[4-(4-Fluorophenoxy)benzenesulfonyl](methyl)amino-N-hydroxy-3-[2-(dimethylamino)ethylsulfanyl]butanamide,  
       2(S)-2-[4-(4-Fluorophenoxy)benzenesulfonyl](methyl)amino-N-hydroxy-3-[(5-methylisoxazol-3-yl)methylsulfanyl]propanamide,  
       2(S)-2-[4-(4-Fluorophenoxy)benzenesulfonyl](methyl)amino-N-hydroxy-3-[(pyrid-2-yl)methylsulfanyl]propanamide,  
       2(S)-2-[4-(4-Fluorophenoxy)benzenesulfonyl](methyl)amino-N-hydroxy-3-[(1-methylimidazol-2-yl)methylsulfanyl]propanamide,  
       2(R), 3(R)-2-[4-(Pyrid-4-yl)oxybenzenesulfonyl](methyl)amino-N,3-dihydroxybutanamide,  
       2(R), 3(R)-2-[4-(Pyrid-4-yl)oxybenzenesulfonyl](methyl)amino-N-hydroxy-3-methoxybutanamide,  
       2(R), 3(R)-2-[4-(Pyrid-4-yl)oxybenzenesulfonyl](methyl)amino-N-hydroxy-3-(2-methoxyethoxy)butanamide,  
       2(R), 3(R), 3(2′(S))-2-[4-(Pyrid-4-yl)oxybenzenesulfonyl](methyl)amino-N-hydroxy-3-[(5-oxopyrrolidin-2-yl)methoxy]butanamide,  
       2(R)-2-[4-(Pyrid-4-yl)oxybenzenesulfonyl](methyl)amino-N-hydroxy-3-methylbutanamide,  
       2(R)-2-[4-(Pyrid-4-yl)oxybenzenesulfonyl](methyl)amino-N-hydroxy-2-cyclohexylacetamide,  
       2(R)-2-[4-(Pyrid-4-yl)oxybenzenesulfonyl](methyl)amino-N-hydroxy-2-cyclopentylacetamide,  
       2(R)-2-[4-(Pyrid-4-yl)oxybenzenesulfonyl](methyl)amino-N-hydroxy-2-cyclopropylacetamide,  
       2(R)-2-[4-(Pyrid-4-yl)oxybenzenesulfonyl](methyl)amino-N-hydroxy-2-(tetrahydro-2H-pyran-4-yl)acetamide,  
       2(S), 3(R)-2-[4-(Pyrid-4-yl)oxybenzenesulfonyl](methyl)amino-N-hydroxy-3-[(5-methylisoxazol-3-yl)methylsulfanyl]butanamide,  
       2(S)-2-[4-(Pyrid-4-yl)oxybenzenesulfonyl](methyl)amino-N-hydroxy-3-[(5-(hydroxymethyl)isoxazol-3-yl)methylsulfanyl]propanamide,  
       2(S)-2-[4-(Pyrid-4-yl)oxybenzenesulfonyl](methyl)amino-N-hydroxy-3-[(phenyl)methylsulfanyl]propanamide,  
       2(S)-2-[4-(Pyrid-4-yl)oxybenzenesulfonyl](methyl)amino-N-hydroxy-3-[(4-fluorophenyl)methylsulfanyl]propanamide,  
       2(S)-2-[4-(Pyrid-4-yl)oxybenzenesulfonyl](methyl)amino-N-hydroxy-3-[(1-methylimidazol-2-yl)methylsulfanyl]propanamide,  
       2(R)-2-[4-(4-Bromophenoxy)benzenesulfonyl](methyl)amino-N-hydroxy-3-methylbutanamide,  
       2(R)-2-[4-(4-Chlorophenoxy)benzenesulfonyl](methyl)amino-N-hydroxy-3-methylbutanamide,  
       2(R)-2-[4-(4-Fluorophenoxy)benzenesulfonyl](methyl)amino-N-hydroxy-3-methylbutanamide,  
       2(R)-2-[4-(4-Methylphenoxy)benzenesulfonyl](methyl)amino-N-hydroxy-3-methylbutanamide,  
       2(R)-2-[4-(4-Methoxyphenoxy)benzenesulfonyl](methyl)amino-N-hydroxy-3-methylbutanamide,  
       2(R)-2-[4-Phenoxybenzenesulfonyl](methyl)amino-N-hydroxy-3-methylbutanamide,  
       2(R)-2-[4-(Biphenyl-4-yl)oxybenzenesulfonyl]-N-hydroxy-piperidine-2-carboxamide,  
       2(R)-2-[4-(4-(Imidazol-1-yl)phenoxy)benzenesulfonyl](methyl)amino-N-hydroxy-3-methylbutanamide,  
       2(R)-2-[4-(4-(Imidazol-2-yl)phenoxy)benzenesulfonyl](methyl)amino-N-hydroxy-3-methylbutanamide,  
       2(R)-2-[4-(4-(Imidazol-4-yl)phenoxy)benzenesulfonyl](methyl)amino-N-hydroxy-3-methylbutanamide,  
       2(R)-2-[4-(4-(2-(dimethylamino)ethyl)phenoxy)benzenesulfonyl](methyl)amino-N-hydroxy-3-methylbutanamide,  
       2(R)-1-[4-(4-Bromophenoxy)benzenesulfonyl]-N-hydroxy-hexahydro-1H-azepine-2-carboxamide,  
       2(R)-1-[4-(4-Chlorophenoxy)benzenesulfonyl]-N-hydroxy-hexahydro-1H-azepine-2-carboxamide,  
       2(R)-1-[4-(4-Fluorophenoxy)benzenesulfonyl]-N-hydroxy-hexahydro-1H-azepine-2-carboxamide,  
       2(R)-1-[4-(4-Methylphenoxy)benzenesulfonyl]-N-hydroxy-hexahydro-1H-azepine-2-carboxamide,  
       2(R)-1-[4-(4-Methoxyphenoxy)benzenesulfonyl]-N-hydroxy-hexahydro-1H-azepine-2-carboxamide,  
       2(R)-1-[4-Phenoxybenzenesulfonyl]-N-hydroxy-hexahydro-1H-azepine-2-carboxamide,  
       2(R)-1-(4-(Biphenyl-4-yl)oxybenzenesulfonyl]-N-hydroxy-hexahydro-1H-azepine-2-carboxamide,  
       2(R)-1-[4-(4-(Imidazol-1-yl)phenoxy)benzenesulfonyl]-N-hydroxy-piperidine-2-carboxamide,  
       2(R)-1-[4-(4-(Imidazol-2-yl)phenoxy)benzenesulfonyl]-N-hydroxy-hexahydro-1H-azepine-2-carboxamide,  
       2(R)-1-[4-(4-(Imidazol-4-yl)phenoxy)benzenesulfonyl]-N-hydroxy-hexahydro-1H-azepine-2-carboxamide,  
       2(R)-1-[4-(4-(Pyrazol-4-yl)phenoxy)benzenesulfonyl]-N-hydroxy-hexahydro-1H-azepine-2-carboxamide,  
       2(R)-1-[4-(4-(Pyrazol-3-yl)phenoxy)benzenesulfonyl]-N-hydroxy-hexahydro-1H-azepine-2-carboxamide,  
       2(R)-1-[4-(4-(2-(Dimethylamino)ethyl)phenoxy)benzenesulfonyl]-N-hydroxy-hexahydro-1H-azepine-2-carboxamide,  
       2(R)-1-[4-(Pyrid-4-yl)oxybenzenesulfonyl]-N-hydroxy-hexahydro-1H-azepine-2-carboxamide,  
       2(R), 3(S)-1-[4-(4-Chlorophenoxy)benzenesulfonyl]-N-hydroxy-3-methyl-hexahydro-1H-azepine-2-carboxamide,  
       2(R), 3(S)-1-[4-(4-Fluorophenoxy)benzenesulfonyl]-N-hydroxy-3-methyl-hexahydro-1H-azepine-2-carboxamide,  
       2(R), 3(S)-1-[4-(4-Methoxyphenoxy)benzenesulfonyl]-N-hydroxy-3-methyl-hexahydro-1H-azepine-2-carboxamide,  
       2(R), 3(S)-1-[4-(4-(Imidazol-1-yl)phenoxy)benzenesulfonyl]-N-hydroxy-3-methyl-hexahydro-1H-azepine-2-carboxamide,  
       2(R), 3(S)-1-[4-(4-(Imidazol-2-yl)phenoxy)benzenesulfonyl]-N-hydroxy-3-methyl-hexahydro-1H-azepine-2-carboxamide,  
       2(R), 3(S)-1-[4-(4-(Imidazol-4-yl)phenoxy)benzenesulfonyl]-N-hydroxy-3-methyl-hexahydro-1H-azepine-2-carboxamide,  
       2(R), 3(S)-1-[4-(4-(Pyrazol-4-yl)phenoxy)benzenesulfonyl]-N-hydroxy-3-methyl-hexahydro-1H-azepine-2-carboxamide,  
       2(R), 3(S)-1-[4-(4-(Pyrazol-3-yl)phenoxy)benzenesulfonyl]-N-hydroxy-3-methyl-hexahydro-1H-azepine-2-carboxamide, or  
       2(R), 3(S)-1-[4-(Pyrid-4-yl)oxybenzenesulfonyl]-N-hydroxy-3-methyl-hexahydro-1H-azepine-2-carboxamide;  
       or a pharmaceutically acceptable prodrug, salt, or solvate thereof.  
     
     
       13. A pharmaceutical composition comprising: 
       (a) a therapeutically effective amount of a compound as defined in claim  1  or a pharmaceutically acceptable prodrug, salt, or solvate thereof; and  
       (b) a pharmaceutically acceptable carrier, diluent, vehicle, or excipient.  
     
     
       14. A method of treating a mammalian disease condition mediated by metalloproteinase activity which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound as defined in claim  1  or a pharmaceutically acceptable prodrug, salt, or solvate thereof. 
     
     
       15. A method according to claim  14 , wherein the mammalian disease condition is tumor growth, invasion, or metastasis. 
     
     
       16. A method according to claim  14 , wherein the mammalian disease condition is osteoarthritis, rheumatoid arthritis, osteoporosis, periodontitis, or gingivitis. 
     
     
       17. A method according to claim  14 , wherein the mammalian disease condition is chronic dermal wounds, corneal ulceration, or degenerative skin disorders. 
     
     
       18. A method according to claim  14 , wherein the mammalian disease condition is multiple sclerosis or stroke. 
     
     
       19. A method according to claim  14 , wherein the mammalian disease condition is atherosclerosis or glomerular disease. 
     
     
       20. A method according to claim  14 , wherein the mammalian disease condition is characterized by unwanted angiogenesis. 
     
     
       21. A method according to claim  14 , wherein the mammalian disease condition is diabetic retinopathy, macular degeneration, angiofibromas, or hemangiomas. 
     
     
       22. A method according to claim  14 , wherein the mammalian disease condition is mediated by matrix metalloproteinase activity. 
     
     
       23. A method according to claim  14 , wherein the mammalian disease condition is mediated by TNF-α convertase activity. 
     
     
       24. A method of inhibiting the activity of at least one metalloproteinase which comprises contacting said at least one metalloproteinase with an effective amount of a compound as defined in claim  1  or a pharmaceutically acceptable prodrug, salt, or solvate thereof. 
     
     
       25. A method according to claim  24 , wherein said at least one metalloproteinase is a matrix metalloproteinase. 
     
     
       26. A method according to claim  25 , wherein said at least one metalloproteinase is a TNF-α convertase.
Cited by (0)

No later patents cite this yet.
References (0)

No backward citations on record.